

Special Issue

Multomics Approaches for Translational Medicine

Message from the Guest Editor

Multiple high-throughput methods for molecular profiling of biological samples have been developed during the last two decades, including various sequencing, microarray, proteomic, and proteogenomic assays. However, so far, only a few have been implemented into clinical practice and guidelines, e.g., exome and target panel sequencing for cancer diagnostics. At the same time, other high-throughput methods, such as RNA sequencing for gene expression profiling and fusion detection, as well as various proteomic assays, provide relevant information on pathological biosamples, allowing discovery and implementation of novel prognostic, diagnostic, and predictive biomarkers. This Special Issue will cover a broad range of experimental and analytical high-throughput tools to be applied to human disease. We welcome manuscripts from, but not limited to, the following subtopics: discovery of novel biomarkers; development of bioinformatic tools for the analysis of multidimensional omics datasets; pathway and whole-interactome analysis; novel methodologies for high-throughput molecular profiling of human biosamples; functional analysis of multomics datasets.

Guest Editor

Dr. Maxim Sorokin

1. Laboratory for Clinical and Genomic Bioinformatics, Institute for Personalized Oncology, Sechenov University, Moscow, Russia
2. Laboratory for Translational Genomic Bioinformatics, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow, Russia
3. Department of Bioinformatics and Molecular Networks, OmicsWay Corp., Walnut, CA, USA

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/135301

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).